Viracta Therapeutics, Inc. (VIRX)

NASDAQ: VIRX · IEX Real-Time Price · USD
4.37
+0.14 (3.31%)
Sep 28, 2022 4:00 PM EDT - Market closed
3.31%
Market Cap 164.13M
Revenue (ttm) n/a
Net Income (ttm) -47.49M
Shares Out 37.56M
EPS (ttm) 1.49
PE Ratio 2.93
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 104,999
Open 4.27
Previous Close 4.23
Day's Range 4.15 - 4.69
52-Week Range 1.82 - 8.16
Beta n/a
Analysts Buy
Price Target 21.83 (+399.5%)
Earnings Date Nov 8, 2022

About VIRX

Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket trial for the treatment of various relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngea... [Read more...]

Industry Biotechnology
Founded 2007
CEO Dayton Misfeldt
Employees 31
Stock Exchange NASDAQ
Ticker Symbol VIRX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for VIRX stock is "Buy." The 12-month stock price forecast is 21.83, which is an increase of 399.54% from the latest price.

Price Target
$21.83
(399.54% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Viracta Therapeutics Announces New Employment Inducement Grant

SAN DIEGO, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that, in connection with th...

1 week ago - GlobeNewsWire

Viracta Therapeutics Announces Chief Executive Officer Leadership Succession to Drive the Next Phase of the Company's...

Viracta Therapeutics' Board of Directors appoints Mark Rothera as President and Chief Executive Officer Founding President and CEO Ivor Royston, M.D., will continue to serve as a Member of Viracta's Boa...

1 week ago - PRNewsWire

Does Sunesis (VIRX) Have the Potential to Rally 335% as Wall Street Analysts Expect?

The consensus price target hints at a 334.8% upside potential for Sunesis (VIRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate r...

2 weeks ago - Zacks Investment Research

Viracta (VIRX) Up on Orphan Drug Tag for Peripheral Lymphoma

Viracta (VIRX) receives Orphan Drug designation from the European Commission for its lead candidate Nana-val for treating peripheral T-cell lymphoma. Stock up.

2 weeks ago - Zacks Investment Research

Viracta Therapeutics Announces Orphan Drug Designation Granted by the European Commission for Nana-val for the Treatm...

First orphan drug designation granted for Nana-val by the European Commission; fifth globally SAN DIEGO , Sept. 7, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology co...

3 weeks ago - PRNewsWire

Viracta Therapeutics Chief Scientific Officer, Dr. Ayman Elguindy, Elected to the Governing Board of the Internationa...

SAN DIEGO , Aug. 16, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that the International Associat...

1 month ago - PRNewsWire

Viracta Therapeutics Appoints Jane Chung, R.Ph., to its Board of Directors

SAN DIEGO , Aug. 11, 2022 /PRNewswire/ -- Viracta  Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the appointment of Jane Chung,...

1 month ago - PRNewsWire

Viracta Therapeutics Reports Second Quarter 2022 Financial Results and Recent Updates

Continued progress of NAVAL-1, the pivotal trial of Nana-val for the treatment of Epstein-Barr virus-positive (EBV+) lymphoma; update on the initial cohort(s) expanding into Stage 2 is anticipated in th...

1 month ago - PRNewsWire

Here's Why Viracta Therapeutics (VIRX) is Up So Far This Year

Viracta Therapeutics' (VIRX) Nana-val is being evaluated in multiple clinical studies in various subtypes of EBV-associated cancers.

2 months ago - Zacks Investment Research

4 Small Stocks to Bet on in an Upbeat Drugs Industry

It is expected that innovation will continue to drive growth in the Medical-Drugs industry in 2022. KDNY, ASRT, VIRX, SLNO may prove to be good additions to one's portfolio.

Other symbols: ASRTKDNYSLNO
2 months ago - Zacks Investment Research

Viracta Therapeutics President and Chief Executive Officer Dr. Ivor Royston Receives the Science History Institute's ...

SAN DIEGO , June 13, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that its President and Chief Ex...

3 months ago - PRNewsWire

Viracta Therapeutics Provides an Update on the Phase 1b/2 Trial of Nana-val in Patients with Advanced Epstein-Barr Vi...

Trial has advanced to the second dose escalation cohort with no dose-limiting toxicities observed to-date SAN DIEGO , June 2, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision ...

3 months ago - PRNewsWire

Viracta Therapeutics to Present at the Jefferies Healthcare Conference

SAN DIEGO , June 1, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company management is sched...

3 months ago - PRNewsWire

Viracta Therapeutics to Present at Upcoming May Investor Conferences

SAN DIEGO , May 11, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company management will pre...

4 months ago - PRNewsWire

Viracta Therapeutics Reports First Quarter 2022 Financial Results and Recent Updates

Continued global expansion of NAVAL-1, the pivotal trial of Nana-val for the treatment of Epstein-Barr virus-positive (EBV+) lymphoma; update on the initial cohort(s) that have advanced into Stage 2 ant...

4 months ago - PRNewsWire

Viracta Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

SAN DIEGO , April 7, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company leadership is sche...

5 months ago - PRNewsWire

Viracta Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference

SAN DIEGO, March 9, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company leadership is sched...

6 months ago - PRNewsWire

Viracta Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

SAN DIEGO, Feb. 10, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that Dr. Ivor Royston, the compa...

7 months ago - PRNewsWire

Viracta Therapeutics Announces First Patient Dosed in Phase 1b/2 Trial of Nana-val in Patients with Advanced Epstein-...

SAN DIEGO, Jan. 31, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that the first patient has been ...

7 months ago - PRNewsWire

Viracta Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

SAN DIEGO, Jan. 4, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company management is schedu...

8 months ago - PRNewsWire

Viracta Therapeutics to be Added to the Nasdaq Biotechnology Index

SAN DIEGO, Dec. 16, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that it has been selected for ad...

9 months ago - PRNewsWire

Viracta Therapeutics Presents Preclinical Vecabrutinib Data in Oral and Poster Presentations at ASH 2021

SAN DIEGO, Dec. 13, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the presentation of new preclini...

9 months ago - PRNewsWire

Viracta Therapeutics Posts Data From Lymphoma Trial At ASH Presentation

Viracta Therapeutics Inc (NASDAQ: VIRX) announced final data from its Phase 1b/2 trial of Nana-val in relapsed/refractory (R/R) EBV+ lymphoma. The data were presented at the 2021 American Society of Hem...

9 months ago - Benzinga

Viracta Therapeutics Announces Final Phase 1b/2 Data Showing Promising and Durable Signal of Efficacy for Nana-val in...

SAN DIEGO, Dec. 13, 2021 /PRNewswire/ --  Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that final data from its Phase ...

9 months ago - PRNewsWire

Viracta Therapeutics Announces Orphan Drug Designation Granted by FDA for its All-Oral Combination of Nanatinostat an...

SAN DIEGO, Nov. 29, 2021 /PRNewswire/ --  Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that the U.S. Food and Drug Adm...

9 months ago - PRNewsWire